One notable advancement in cancer treatment is the development of EZH2 inhibitors, with tazemetostat being a key example that has received FDA approval for patients with both hematologic and solid tumors (Straining and Eighmy, 2022) (Figure 1). The gene discussed is EZH2; the disease is cancer.